Evidence map›Paper›PMID 38737642›Full record

ReviewAmerican journal of nuclear medicine and molecular imaging2024

Radiodifluoromethylation of well-functionalized molecules.

Wei Zhang, Yinlong Li, Steven H Liang

Abstract readReview
In one paragraph

Review in American journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wei ZhangDepartment of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, USA.
Yinlong LiDepartment of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, USA.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, USA.

Funding

PET ligand discovery for arginine vasopressinR01MH128705 · NIMH · EMORY UNIVERSITY · PI Steven H Liang · 2022 to 2026
$5.8M
Subtype-Selective Metabotropic Glutamate Receptor PET LigandsR61NS130128 · NINDS · EMORY UNIVERSITY · PI Steven H Liang · 2023 to 2026
$2.4M
AMPAR ligand discovery for Alzheimer's diseaseRF1AG073428 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2021 to 2021
$2.3M
Subtype-selective phosphodiesterase PET ligandsR01AG079956 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2023 to 2025
$2.3M
AMPAR ligand discovery for Alzheimer's diseaseR01AG073428 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2024 to 2025
$1.5M
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's diseaseR21AG080262 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2023 to 2024
$430k
NIA NIH HHS R01 AG073428NIA NIH HHS R01 AG079956NIA NIH HHS R21 AG080262NIA NIH HHS RF1 AG073428NIMH NIH HHS R01 MH128705NINDS NIH HHS R61 NS130128
6 · The paper itself

Abstract

The strategic installation of a [

Indexed as

[18F]difluorocarbene[18F]difluoromethylationfrustrated Lewis pairpositron emission tomography

Identifiers

PMID38737642
PMCPMC11087296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.